Lantern Pharma Inc. reported a net loss of $4.2 million for the third quarter of 2025, compared to a net loss of $4.5 million in the same period of 2024. Net loss per common share, basic and diluted, was $0.39, down from $0.42 in the prior year period. Total operating expenses were $4.3 million, a decrease from $5.2 million in 2024. Cash, cash equivalents, and marketable securities totaled $12.4 million as of September 30, 2025, compared to $24.0 million at the end of 2024. Total assets were $13.6 million, with total liabilities of $4.0 million and stockholders' equity of $9.6 million. Key business developments for the period included completion of the Phase 1a clinical trial for LP-184, achieving all primary endpoints with a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic dose threshold. Lantern Pharma also advanced enrollment in the first-in-human clinical trial for LP-284 in non-Hodgkin lymphoma and other cancers, and reported initial clinical data for the Asian cohort in the Harmonic Trial. The company progressed its Starlight Therapeutics subsidiary toward planned Phase 1/2 clinical trials and expanded its RADR AI platform, preparing to launch initial modules as open-source AI agents.